Press Release Archive
-
Crohn’s Disease Patients Refractory To Tumor Necrosis Factor Inhibitors Showed Improvement In Disease With STELARA® TreatmentSTELARA Phase 2b Crohn’s Disease Study Published in The New England Journal of Medicine
-
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2012
-
Johnson & Johnson Reports 2012 Third-Quarter ResultsSales of $17.1 Billion increased 6.5% Versus 2011 Third Quarter; Third-Quarter EPS was $1.05Excluding Special Items, 2012 Third-Quarter EPS of $1.25 increased 0.8%*
-
Cordis Corporation Announces One-Year Results from the STROLL TrialTrial Assesses the Safety and Efficacy of the S.M.A.R.T.® Nitinol Self-Expandable Stent System in the Superficial Femoral Artery*
-
First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes at an Elevated Risk for Cardiovascular DiseaseCanagliflozin also shown effective and generally well-tolerated in patients with type 2 diabetes aged 55 to 80 in separate Phase 3 study
-
Janssen Announces Worldwide Agreement To Develop And Commercialize JAK Inhibitor For Immunological DiseasesOrally Administered Investigational Therapy Expands Global Immunology Portfolio
-
Janssen Presents Sustainable Health Care Programs at CleanMed Europe Conference, Malmo, Sweden
-
Depuy Mitek Launches Next Generation Rotator Cuff AnchorNew HEALIX ADVANCE™ Family of Suture Anchors Offers High Strength Repair, Surgical Versatility and Ease of Use
-
James E. Burke, Former Chairman and CEO of Johnson & Johnson, Dies at 87
-
New ZYTIGA® (abiraterone acetate) Data on Pain and Function Presented at the ESMO 2012 Congress (European Society for Medical Oncology)New Analyses from Phase 3 COU-AA-302 Study Also Suggest Radiographic Progression-Free Survival Positively Associated with Overall Survival